Printing Gk22/Gk23r1 as Blinded for Non-Blinded Study Products in PMDA E2B R3 Paper Report in Argus Safety Japan
(Doc ID 2418079.1)
Last updated on JULY 13, 2023
Applies to:
Oracle Life Sciences Argus Safety - Version 8.1.2 to 8.1.2 [Release 8.1]Oracle Life Sciences Argus Safety Japan - Version 8.1.2 to 8.1.2 [Release 8.1]
Information in this document applies to any platform.
Symptoms
Configure a study with these products:
- a CDD drug with "Blinded" checkbox checked (e.g., main IMP)
- a CDD drug with "Blinded" checkbox checked (e.g., placebo)
- a CDD drug with "Blinded" checkbox is NOT checked (e.g., OXALIPLATIN)
Book in a case for the study.
Two product tabs are automatically created; one for the blinded part and one for the non-blinded product. For example:
Enter all the required data for the non-blinded products in the case.
Schedule and generate a PMDA E2B R3 paper form with 'Do you want to hide unblinded information?' = Y
In the Product sections of the report, G.k.2.2 MEDICINALPRODUCT and G.k.2.3.r.1 ACTIVESUBSTANCENAME appear as blinded for the non-blinded study products configured above:
The problem also occurs for any non-blinded products added in the Case Form > Products tab.
Changes
Cause
To view full details, sign in with your My Oracle Support account. |
|
Don't have a My Oracle Support account? Click to get started! |
In this Document
| Symptoms |
| Changes |
| Cause |
| Solution |
| References |